Abiraterone Risk Higher in Prostate Cancer Patients Who Have CVD Abiraterone Risk Higher in Prostate Cancer Patients Who Have CVD

A new analysis finds that men with prostate cancer treated with abiraterone acetate have a significantly higher mortality if they also have preexisting cardiovascular disease.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news